Biocompatibility of poloxamer hydrogel as an injectable intraocular lens

Kwon, Ji Won; Han, Young Keun; Lee, Woojin; Cho, Chong Su; Paik, Seung Joon; Cho, Dong Il; Lee, Jin Hak; Wee, Won Ryang

doi:10.1016/j.jcrs.2004.05.051

Cited by 42 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hydrogel remained stable and kept its integrity for up to six months. In their study, no inflammation or toxicity for conjunctiva, cornea, iris, vitreous, and retina were observed [23]. In our study, however, the injected Pluronic F127 dissolved in the vitreous within two days.…”

Section: Resultscontrasting

confidence: 68%

Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl Oxazoline)-Block-Poly(ε-Caprolactone)-Block-Poly(2-Ethyl Oxazoline) Copolymer, Matrigel and Pluronic F127

et al. 2013

View full text Add to dashboard Cite

The long term in vivo biocompatibility is an essential feature for the design and development of sustained drug release carriers. In the recent intraocular drug delivery studies, hydrogels were suggested as sustained release carriers. The biocompatibility test for these hydrogels, however, was commonly performed only through in vitro cell culture examination, which is insufficient before the clinical applications. We compared three thermosensitive hydrogels that have been suggested as the carriers for drugs by their gel-solution phase-change properties. A new block terpolymer (PEOz-PCL-PEOz, ECE) and two commercial products (Matrigel® and Pluronic F127) were studied. The results demonstrated that the ocular media remained translucent for ECE and Pluronic F127 in the first 2 weeks, but cataract formation for Matrigel occurred in 2 weeks and for Pluronic F127 in 1 month, while turbid media was observed for both Matrigel and Pluronic F127 in 2 months. The electrophysiology examinations showed significant neuroretinal toxicity of Matrigel and Pluronic F127 but good biocompatibility of ECE. The neuroretinal toxicity of Matrigel and Pluronic F127 and superior biocompatibility of ECE hydrogel suggests ECE as more appropriate biomaterial for use in research and potentially in intraocular application.

show abstract

Section: Resultscontrasting

confidence: 68%

Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl Oxazoline)-Block-Poly(ε-Caprolactone)-Block-Poly(2-Ethyl Oxazoline) Copolymer, Matrigel and Pluronic F127

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Recently, an injectable intraocular lens formulation containing 25% Poloxamer 407 produced no inflammatory response or toxicity in the conjunctiva, iris, vitreous or retina using New-Zealand white rabbits (96). To reduce gradual elimination of Poloxamer 407 after intraocular injection, a photoinitiator was added to induce irreversible gelation and resolved the problem of the poloxamer slowly dissolving in the lens capsule (96). In vivo studies of contact-time were performed with two human subjects using Poloxamer 407 gel containing fluorescent microparticles (Fluorescein-5-isothiocyanate-labeled Sephadex G25 superfine \ ) to facilitate visualisation.…”

Section: Ophthalmic Formulationmentioning

confidence: 99%

A Review of Poloxamer 407 Pharmaceutical and Pharmacological Characteristics

et al. 2006

View full text Add to dashboard Cite

Poloxamer 407 copolymer (ethylene oxide and propylene oxide blocks) shows thermoreversible properties, which is of the utmost interest in optimising drug formulation (fluid state at room temperature facilitating administration and gel state above sol-gel transition temperature at body temperature promoting prolonged release of pharmacological agents). Pharmaceutical evaluation consists in determining the rheological behaviour (flow curve or oscillatory studies), sol-gel transition temperature, in vitro drug release using either synthetic or physiological membrane and (bio)adhesion characteristics. Poloxamer 407 formulations led to enhanced solubilisation of poorly water-soluble drugs and prolonged release profile for many galenic applications (e.g., oral, rectal, topical, ophthalmic, nasal and injectable preparations) but did not clearly show any relevant advantages when used alone. Combination with other excipients like Poloxamer 188 or mucoadhesive polymers promotes Poloxamer 407 action by optimising sol-gel transition temperature or increasing bioadhesive properties. Inclusion of liposomes or micro(nano)particles in Poloxamer 407 formulations offers interesting prospects, as well. Besides these promising data, Poloxamer 407 has been held responsible for lipidic profile alteration and possible renal toxicity, which compromises its development for parenteral applications. In addition, new findings have demonstrated immuno-modulation and cytotoxicity-promoting properties of Poloxamer 407 revealing significant pharmacological interest and, hence, human trials are in progress to specify these potential applications.

show abstract

“…Among therapeutics, adsorbent coatings for blood perfusion, 208-211 hemodialysis membranes, [212][213][214][215][216] blood oxygenators, 214 degradable drug delivery systems, medicated and soft contact lenses should be mentioned. [217][218][219][220][221] Implants include intraocular lenses, 222,223 artificial corneas, [224][225][226][227][228] coating for drainage tubes and stents, [229][230][231][232] vitreous humor replacements, 233 soft tissue substitutes/replacements, 126,234,235 burn dressing, [236][237][238][239][240][241] bone ingrowth sponges, 242 plastic surgery, [243][244][245] scleral buckling implants for retinal surgery. [246][247][248][249] Finally, as pure TE products, temporal artificial skin substitutes, membranes used to prevent postoperation adhesion and to promote healing, 250 HGs produced in vivo by using in situ photopolymerization, 9,10,35,37,202,…”

Section: Biomedical/tissue Engineering Applicationsmentioning

confidence: 99%